Clinical trial NCT02878694: Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft
Official title: Treatment of Ptosis to Muscular Dystrophy Oculopharyngeal by Myoblast Autologous Graft
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
PHASE3
Conditions: Muscular Dystrophy, Oculopharyngeal
Ptosis
Lead sponsor: University Hospital, Caen
Sponsor class: OTHER
Collaborators: name: University Hospital, Rouen
name: Rennes University Hospital
name: Centre Hospitalier Universitaire, Amiens
name: University Hospital, Lille
name: University Hospital, Brest
name: Groupe Hospitalier Pitie-Salpetriere
First posted: 2016-08-25
Enrollment: 1
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Interventional , multicenter , comparative study. One eye receiving the cells and the contralateral eye as a negative control . If effectiveness following review of the primary endpoint and the advice of an independent expert committee , the experimental treatment will be offered to the patient to the contralateral eyelid.

Objective is to restore muscle function levator muscle of the upper eyelid by providing a registry of autologous myoblasts from a non- clinically affected muscle .

Detailed description: Muscular dystrophy oculopharyngeal ( OPMD ) is an autosomal dominant inherited myopathy manifested as selective involvement of the levator muscles of the upper eyelids , head of ptosis, and muscles of the intersection pharyngolaryngeal originally disorders swallowing. Ptosis can be treated with surgery ( shortening of the levator muscle ), but the disease continues to evolve , relapses occur , necessitating another intervention , which is the suspension of the eyelid to the frontal muscle that can cause corneal complications by imperfect lid closure .

Main objective is to restore muscle function levator muscle of the upper eyelid by providing a registry of autologous myoblasts from a non- clinically affected muscle .

A study on the same model was conducted in patients in ENT OPMD crossroads of muscles with encouraging results , 12/12 patients had improved quality of life and no degradation of swallowing was observed in 10 / 12 patients.

This is an interventional study , multicenter, comparative , one eye receiving the cells and the contralateral eye as a negative control . If effectiveness following review of the primary endpoint and the advice of an independent expert committee , the experimental treatment will be offered to the patient to the contralateral eyelid.

Seven centers are associated with this project as inclusion and assessment center. Patients are referred by different clinical sites in Caen ophthalmology department which will be performed pre-transplant assessment, the collection of donor myoblast muscle graft and part tracking.

The expected duration is 3 years (2 years of inclusion and evaluation of the primary endpoint at 1 year) for inclusion of 10 patients.

The safety of autologous myoblast transplantation has been shown in several directions with promising efficacy results. They will be produced by the unit of Biotherapy Rouen University Hospital (Prof. O. Boyer), who currently leads a test with these cells (ClinicalTrials.gov, myoblast for Anal Incontinence (MIAS), NCT01523522, 24 patients were provided in Protocol was included in July 2014, at 6 months follow up of the last patient is expected in January 2015) and authorized the production of advanced therapy medicinal products prepared punctually (ANSM).

In this study, different successive steps:

* Step of including: patient aged 18 to 75, verification of the diagnosis of the disease, evaluation balance ptosis (measurements, photographs, films), obtaining consent,
* Muscle biopsy of a healthy muscle to cell amplification, an outpatient basis, under local anesthesia, 3 to 4 weeks before transplantation,
* Transplant myoblasts by multiple intramuscular injections (6), under local anesthesia. Longitudinal microscarifications be made superficially injected into muscles to stimulate muscle regeneration. Intramuscular injection of myoblasts will be in the levator muscle of the upper lid 6 in equidistant points, each injection containing 5 million cells. These injections will be made in muscle mass over an area of about 5 cm2, ranging between 6 and 20 mm above the tarsus to be in the thick muscle area. It is intended to be injected into the eye to treat randomized a total of 30 million myoblasts. This protocol is based on the one used for correction of ENT disorders within several PHRC under the responsibility of Professor Sophie Périé. The doses used for the myoblast transplantation in the pharyngeal constrictor muscles were adapted to the levator muscle of the eyelid.
* Follow-up visits for 3 years for each patient:

  * The first year, to evaluation of the primary endpoint visit to 8 days to a month, then every 3 months
  * Out protocol and up to 3 years after administration of the cells every 6 months (this monitoring will be carried out as part of standard care).

These visits evaluate the effectiveness of the transplant on different objective measurements on both eyes (eyelid opening slot in the gaze straight ahead; levator muscle strength of the upper eyelid, visual benefit: measurement of visual acuity measurement visual field), and the profit on neck pain. The tours include a side effect detection examination (local inflammatory phenomena, palpable lumps).

In the end, this landmark trial for the new F.H.U. SURFACE dealing with regenerative medicine in the head and neck, the investigators expect an improvement in the quality of the levator of the upper eyelid muscles deficient with a correction of ptosis in patients.

Eligibility criteria: Inclusion Criteria:

* Male or female ( with suitable contraception) over 18 years of age 75
* OPMD confirmed by genetic diagnosis ( gene mutation PABPN1 by triplet expansion GCG)
* OPMD with ptosis
* Obtaining informed consent signed

Exclusion Criteria:

* Evolutionary contagious infectious pathology
* Inflammatory diseases
* Any other neuromuscular disease
* Malignant tumor pathology of history
* Renal impairment ( creatinine clearance \< 60ml / min)
* Hepatic insufficiency
* Pregnant woman confirmed by a dosing B-HCG or lactating
* Inability to perform a muscle biopsy
* Preparation of myoblasts uncommitted to step 2nd release
* Inability to follow up to 36 months
* Refusal to sign the consent form
* No Social Security

Primary outcomes:
measure: Improvement of ptosis
timeFrame: baseline and 12 months
Secondary outcomes:
measure: acuity
timeFrame: 12 months
measure: Goldmann Visual Field
timeFrame: 12 months
measure: neck pain with Visual Analaogue Scale
timeFrame: 12 months
measure: Tolerance of the sampling procedure and transplantation, swelling (yes / no)
timeFrame: baseline
measure: Tolerance of the sampling procedure and transplantation : visual analogue scale Pain about the procedure
timeFrame: baseline
measure: Tolerance of collection of the seat and transplantation: hematoma (yes / no )
timeFrame: baseline
measure: fever
timeFrame: baseline
measure: strength of the levator muscle of the upper eyelid
timeFrame: 12 months
Other outcomes:
Locations:
city: Caen
country: France
facility: CHU Caen
Study officials:
affiliation: CHU CAEN
name: Françoise CF Chapon, PhD
role: STUDY_CHAIR
affiliation: CHU Rouen
name: Olivier BO Boyer, PhD
role: STUDY_CHAIR
affiliation: CHU Rennes
name: Frederic MF Mouriaux, PhD
role: STUDY_CHAIR
affiliation: APHP
name: Sophie PS Perie, PhD
role: STUDY_CHAIR
References: